Short answer
Neurocrine Biosciences Inc (NBIX) filed its Q1 2018 10-Q quarterly report on Apr 30, 2018 for the quarter ended Mar 31, 2018.
Neurocrine Biosciences Inc Q1 2018 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $71.1M, versus no product sales in Q1 2017, entirely from INGREZZA
- Gross margin 98.6%, based on $1.0M cost of product sales
- Net loss $41.8M vs $78.3M YoY, loss per share $0.47 vs $0.90
- Cash, equivalents and investments $736.8M vs $763.3M at December 31, 2017
- Operating cash use $38.5M vs $77.4M YoY, capital resources expected sufficient for at least 12 months
Risk Factors
- No material changes stated, except starred factors revised or added since the 2017 10-K
- Organizational growth risk: approximately 440 employees as of March 31, 2018, increasing management and infrastructure demands
- Regulatory compliance risk: expanded post-marketing obligations for INGREZZA could lead to approval withdrawal or penalties
- Competitive risk: Teva’s AUSTEDO approval in August 2017 creates direct tardive dyskinesia competition
- Financial risk: $517.5 million of 2.25% convertible notes due 2024, with potential liquidity pressure upon conversion
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Neurocrine Biosciences Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.